Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Randomized Trial of Post-Operative Biomarker-Guided Precision Medicine With Rivaroxaban and Atorvastatin for Cardiovascular Risk-Reduction

NCT06961630 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT06961630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06961630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Randomized Trial of Post-Operative Biomarker-Guided Precision Medicine With Rivaroxaban and Atorvastatin for Cardiovascular Risk-Reduction
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Recruiting
Start date
October 7, 2025
Completion date
March 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial injury after noncardiac surgery